HTTP 200 OK
Allow: GET
Content-Type: application/json
Vary: Accept
{
"url": "https://lda.senate.gov/api/v1/filings/470b90ae-1923-44ba-b2da-e0f5b32aeb03/?format=api",
"filing_uuid": "470b90ae-1923-44ba-b2da-e0f5b32aeb03",
"filing_type": "Q4",
"filing_type_display": "4th Quarter - Report",
"filing_year": 2025,
"filing_period": "fourth_quarter",
"filing_period_display": "4th Quarter (Oct 1 - Dec 31)",
"filing_document_url": "https://lda.senate.gov/filings/public/filing/470b90ae-1923-44ba-b2da-e0f5b32aeb03/print/",
"filing_document_content_type": "text/html",
"income": "20000.00",
"expenses": null,
"expenses_method": null,
"expenses_method_display": null,
"posted_by_name": "Robert Hobart",
"dt_posted": "2026-01-18T14:57:47-05:00",
"termination_date": null,
"registrant_country": "United States of America",
"registrant_ppb_country": null,
"registrant_address_1": "511 Union Street",
"registrant_address_2": "Suite 1820",
"registrant_different_address": false,
"registrant_city": "Nashville",
"registrant_state": "TN",
"registrant_zip": "37219",
"registrant": {
"id": 401103475,
"url": "https://lda.senate.gov/api/v1/registrants/401103475/?format=api",
"house_registrant_id": 401103475,
"name": "VENTURE GOVERNMENT STRATEGIES, LLC (FKA HOBART HALLAWAY & QUAYLE VENTURES, LLC)",
"description": "government relations and public affairs",
"address_1": "511 Union Street",
"address_2": "Suite 1820",
"address_3": null,
"address_4": null,
"city": "Nashville",
"state": "TN",
"state_display": "Tennessee",
"zip": "37219",
"country": "US",
"country_display": "United States of America",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"contact_name": "ROBERT HOBART",
"contact_telephone": "+1 202-285-8967",
"dt_updated": "2025-07-29T10:46:49.875678-04:00"
},
"client": {
"id": 206609,
"url": "https://lda.senate.gov/api/v1/clients/206609/?format=api",
"client_id": 595,
"name": "CLINICAL REFERENCE LABORATORY, INC.",
"general_description": "privately held clinical testing laboratory",
"client_government_entity": false,
"client_self_select": null,
"state": "KS",
"state_display": "Kansas",
"country": "US",
"country_display": "United States of America",
"ppb_state": "KS",
"ppb_state_display": "Kansas",
"ppb_country": "US",
"ppb_country_display": "United States of America",
"effective_date": "2020-07-06"
},
"lobbying_activities": [
{
"general_issue_code": "MED",
"general_issue_code_display": "Medical/Disease Research/Clinical Labs",
"description": "Policies and regulations impacting clinical laboratories and drug testing, including issues related to HHS and DOT; H.R.4320, Drug and Alcohol Clearinghouse Public Safety Improvement Act of 2025; DOT Rule 49 CFR Part 40 Section 40.82.",
"foreign_entity_issues": "",
"lobbyists": [
{
"lobbyist": {
"id": 72792,
"prefix": null,
"prefix_display": null,
"first_name": "KEVIN",
"nickname": null,
"middle_name": null,
"last_name": "YODER",
"suffix": null,
"suffix_display": null
},
"covered_position": null,
"new": false
}
],
"government_entities": [
{
"id": 2,
"name": "HOUSE OF REPRESENTATIVES"
},
{
"id": 1,
"name": "SENATE"
},
{
"id": 40,
"name": "Transportation, Dept of (DOT)"
}
]
}
],
"conviction_disclosures": [],
"foreign_entities": [],
"affiliated_organizations": []
}